Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ann LaCasce

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Leukemia and Lymphoma

English

Related publications

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Journal of Clinical Oncology

English

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Journal of Clinical Oncology

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

English

Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

American Journal of Hematology

Hematology

2017

English

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

Hematological Oncology

English

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

British Journal of Haematology

Hematology

2018

English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

English

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Hematological Oncology

English

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Ann LaCasce

Therapy With Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Final Results of a Phase II Trial (CALGB 50501)

Related publications

Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma

The Immunologic Doublet of Lenalidomide Plus Obinutuzumab Is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/Ii Study

A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial

Primary Analysis Results of the Single-Arm Phase Ii Study of Mor208 Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (L-Mind)